UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

The Lancet (British edition), 2016-04, Vol.387 (10027), p.1551-1560

2016

Volltextzugriff (PDF)

A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD–56-positive Multiple Myeloma

Clinical lymphoma, myeloma and leukemia, 2019-01, Vol.19 (1), p.29-34

2019

Volltextzugriff (PDF)

Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study

Blood, 2011-07, Vol.118 (4), p.865-873

2011

Volltextzugriff (PDF)

Development of the Histoculture Drug Response Assay (HDRA)

Methods in molecular biology (Clifton, N.J.), 2018-01, Vol.1760, p.39

2018

Volltextzugriff (PDF)

Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis

Blood, 2014-10, Vol.124 (16), p.2498-2506

2014

Volltextzugriff (PDF)

Phase I/II Trial Assessing Bortezomib and Melphalan Combination Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Journal of clinical oncology, 2006-02, Vol.24 (6), p.937-944

2006

Volltextzugriff (PDF)

Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study

Blood, 2009-08, Vol.114 (8), p.1489-1497

2009

Volltextzugriff (PDF)

An open‐label, phase 2 trial of denosumab in the treatment of relapsed or plateau‐phase multiple myeloma

American journal of hematology, 2009-10, Vol.84 (10), p.650-656

2009

Volltextzugriff (PDF)

Purging of Autologous Peripheral-Blood Stem Cells Using CD34 Selection Does Not Improve Overall or Progression-Free Survival After High-Dose Chemotherapy for Multiple Myeloma: Results of a Multicenter Randomized Controlled Trial

Journal of clinical oncology, 2001-09, Vol.19 (17), p.3771-3779

2001

Volltextzugriff (PDF)

A Phase I Dose-ranging Trial of Monthly Infusions of Zoledronic Acid for the Treatment of Osteolytic Bone Metastases

Clinical cancer research, 2001-03, Vol.7 (3), p.478-485

2001

Volltextzugriff (PDF)

Phase 2 study of two sequential three‐drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma

British journal of haematology, 2010-02, Vol.148 (4), p.562-568

2010

Volltextzugriff (PDF)

Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up

Annals of hematology, 2008-08, Vol.87 (8), p.623-631

2008

Volltextzugriff (PDF)

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

The New England journal of medicine, 2016-08, Vol.375 (8), p.754-766

2016

Volltextzugriff (PDF)

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

Leukemia, 2012-01, Vol.26 (1), p.149-157

2012

Volltextzugriff (PDF)

A Phase I Study of Ruxolitinib, Lenalidomide, and Steroids for Patients with Relapsed/Refractory Multiple Myeloma

Clinical cancer research, 2020-05, Vol.26 (10), p.2346-2353

2020

Volltextzugriff (PDF)

Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance

Leukemia, 2019-07, Vol.33 (7), p.1736-1746

2019

Volltextzugriff (PDF)

Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Results of the Z-MARK Study

Clinical cancer research, 2016-03, Vol.22 (6), p.1378-1384

2016

Volltextzugriff (PDF)

Simultaneous Tc-99m PYP/Tl-201 dual-isotope SPECT myocardial imaging in patients with suspected cardiac amyloidosis

Journal of nuclear cardiology, 2020-02, Vol.27 (1), p.28-37

2020

Volltextzugriff (PDF)

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma

Blood, 2009-07, Vol.114 (4), p.772-778

2009

Volltextzugriff (PDF)

Identification of a New, Unorthodox Member of the MAGE Gene Family

Genomics (San Diego, Calif.), 1999-07, Vol.59 (2), p.161-167

1999

Volltextzugriff (PDF)

A Phase I Trial Evaluating the Addition of Lenalidomide to Patients with Relapsed/Refractory Multiple Myeloma Progressing on Ruxolitinib and Methylprednisolone

Targeted oncology, 2024-05, Vol.19 (3), p.343-357

2024

Volltextzugriff (PDF)

Pharmacokinetics and Pharmacodynamics of Zoledronic Acid in Cancer Patients with Bone Metastases

Journal of clinical pharmacology, 2002-11, Vol.42 (11), p.1228-1236

2002

Volltextzugriff (PDF)

Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma

British journal of haematology, 2018-01, Vol.180 (1), p.60-70

2018

Volltextzugriff (PDF)

A phase 3 trial of armodafinil for the treatment of cancer-related fatigue for patients with multiple myeloma

Supportive care in cancer, 2015-06, Vol.23 (6), p.1503-1512

2015

Volltextzugriff (PDF)

Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma

British journal of haematology, 2009-07, Vol.146 (2), p.164-170

2009

Volltextzugriff (PDF)

1 – 25 von 39

Suche als RSS-Feed

Aktive Filter

ThemaMale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(38)
Mit Volltextzugriff
(36)

Publikationsform

Artikel
(39)

Sprache

Englisch
(39)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Female
(39)
Humans
(39)
Life Sciences & Biomedicine
(35)
Science & Technology
(35)
Middle Aged
(34)
Aged
(30)
Adult
(29)
Biological And Medical Sciences
(22)
Multiple Myeloma - Drug Therapy
(21)
Hematology
(20)
Medical Sciences
(20)
Aged, 80 And Over
(19)
Multiple Myeloma
(16)
Oncology
(14)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(13)
Bortezomib
(13)
Treatment Outcome
(11)
Recurrence
(10)
Hematologic And Hematopoietic Diseases
(9)

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD–56-positive Multiple Myeloma

Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study

Development of the Histoculture Drug Response Assay (HDRA)

Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis

Phase I/II Trial Assessing Bortezomib and Melphalan Combination Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study

An open‐label, phase 2 trial of denosumab in the treatment of relapsed or plateau‐phase multiple myeloma

Purging of Autologous Peripheral-Blood Stem Cells Using CD34 Selection Does Not Improve Overall or Progression-Free Survival After High-Dose Chemotherapy for Multiple Myeloma: Results of a Multicenter Randomized Controlled Trial

A Phase I Dose-ranging Trial of Monthly Infusions of Zoledronic Acid for the Treatment of Osteolytic Bone Metastases

Phase 2 study of two sequential three‐drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma

Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

A Phase I Study of Ruxolitinib, Lenalidomide, and Steroids for Patients with Relapsed/Refractory Multiple Myeloma

Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance

Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Results of the Z-MARK Study

Simultaneous Tc-99m PYP/Tl-201 dual-isotope SPECT myocardial imaging in patients with suspected cardiac amyloidosis

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma

Identification of a New, Unorthodox Member of the MAGE Gene Family

A Phase I Trial Evaluating the Addition of Lenalidomide to Patients with Relapsed/Refractory Multiple Myeloma Progressing on Ruxolitinib and Methylprednisolone

Pharmacokinetics and Pharmacodynamics of Zoledronic Acid in Cancer Patients with Bone Metastases

Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma

A phase 3 trial of armodafinil for the treatment of cancer-related fatigue for patients with multiple myeloma

Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma

Aktive Filter

Suchergebnisse filtern